Global EPA And DHA Market Extends at a Healthy CAGR of 6.90% by 2030

Introduction

In consumers' regular meals, EPA and DHA are becoming more significant and prevalent. The prevalence of lifestyle diseases and the number of people seeking preventative healthcare are the main contributors to this development. The newly created applications for EPA and DHA in food, dietary supplements, and clinical nutrition have further propelled the market expansion. There has been a recent buzz regarding novel EPA and DHA sources. Manufacturers are increasingly turning to omega-3 and beta-carotene-rich microalgae as sustainable sources of food and fuel.

Market Dynamics

Significant Growth of Omega-3 Ingredients in Concentrated Forms Drives the Global Market

Omega-3 concentrates are highly refined oils that solely include the essential fatty acids, EPA and DHA, in a handy micro dosage form. This provides the conditions for a particular application and makes it feasible to take enormous amounts comfortably. The usage of high-concentrate fish oils, high-purity krill oils, and purified algal oils is anticipated to increase as supplement customers become more aware of high concentrates and want better convenience and higher omega-3 dosages. Research on novel product formulations is being performed to customize new goods with extra advantages for consumers, focusing on increased absorption/utilization of omega-3 concentrates in dietary supplements and medications.

Upgraded Requirements for EPA in Drugs Applications Create Tremendous Opportunities

EPA is a growing potential segment of the market for omega components due to its distinct health benefits in the domain of adult health. Due to the usage of highly concentrated EPA in heart-healthy drugs, pharmaceutical corporations have taken note. In addition, unlike EPA-based supplements, EPA drugs are highly targeted. They necessitate significant testing and clinical research to prove their safety and efficacy before being approved by the Food and Drug Administration (FDA). Due to this, consumers are now more likely to trust pharmaceutical therapies than dietary supplements. Several market actors have been identified and analyzed to meet the growing demand for EPA omega-3-based product businesses to market and manufacture collaborative medicine.

For instance, Crius Life Sciences' capability to manufacture EPA/DHA at concentration levels customized to the client's demands offers more latitude. Businesses are using krill oil as a replacement for fish oil since fish oil contamination levels are rising. For instance, to create a novel hypertriglyceridemia treatment with krill oil as its primary ingredient, Aker BioMarine, and Acasti Pharma signed a krill oil supply arrangement in November 2019. Over-the-counter products are safer than dietary supplements since they require authorization before selling. Pharmaceutical formulations of omega EPA are very costly, exceedingly pure, and highly concentrated.

Regional Analysis 

Asia-Pacific is the highest revenue contributor and is anticipated to expand at a CAGR of 8.65% over the projection period. China's robust manufacturing sector, burgeoning middle-class population, disposable money, and rising health consciousness among consumers all contribute to the demand for products containing EPA and DHA there. The Chinese are aware of the health advantages of DHA and EPA because many newborn formulae have these omega-3 components, which aid in brain and eye development. Fish oil-derived DHA was previously accepted officially in China as a dietary supplement that may be added to baby formula and kid-friendly cuisine.

North America is anticipated to grow at a CAGR of 5.65% and produce USD 923.60 million during the projection period. Innovations in both products and technologies drive the US market. The best companies are investing in technology to develop superior omega components for usage in a broader range of industries, such as, for example, pharmaceuticals, nutraceuticals, infant nutrition, and food and beverage. In October 2016, DSM unveiled 3C technology, a fresh process innovation. Thanks to technology, producers of omega-3 can create substances that are up to 85% more concentrated. It also makes it simpler for manufacturers to design distinctive EPA and DHA combinations for medications and dietary supplements.

Key Highlights

• The global EPA and DHA market was valued at USD 1,711.60 million in 2022. It is projected to reach USD 3,120.34 million by 2031, growing at a CAGR of 6.90% during the forecast period (2023-2031).
• Based on type, the global EPA and DHA market is bifurcated into Eicosapentaenoic Acid (EPA), Docosahexaenoic Acid (DHA). The docosahexaenoic acid (DHA) segment is the highest contributor to the market and is estimated to boost at a CAGR of 7.20% during the forecast period.
• Based on the source, the global EPA and DHA market is bifurcated into fish oil, algae oil, krill oil, and other sources. The fish oil segment is the highest contributor to the market and is estimated to boost at a CAGR of 7.90% during the forecast period.
• Based on application, the global EPA and DHA market is bifurcated into infant formulae, dietary supplements, fortified food and beverages, pharmaceuticals, and other applications. The dietary supplements segment is the highest contributor to the market and is estimated to boost at a CAGR of 6.30% during the forecast period.
• Asia-Pacific is the most significant revenue contributor and is expected to grow at a CAGR of 8.65% during the forecast period.

Competitive Players

Competitive Players

The global EPA and DHA market's major companies are Koninklijke DSM NV, KD Pharma Group, The Archer Daniels Midland Company, Corbion NV, Novasep Holding SAS, Neptune Wellness Solutions, BASF SE, Omega Protein Corporation, Croda International PLC, Novotech Nutraceuticals, and Polaris SA.

Recent Developments

Market News

• In September 2021, Omega-3 products made from algae that are vegan and sustainable were introduced by KD Pharma Group. Omega-3 concentrates in a variety of forms can be produced thanks to KD Nutra's cutting-edge technology and production versatility. This means that the business can adjust the EPA and DHA ratio based on customer preferences, and for every variety of kd-pür® fish oil, there is an equivalent Alga3TM plant-based alternative.
• In June 2021, Omegavie® DHA 800 Sensory Qualitysilver ® 5 algae, a high-concentration microalgae DHA ingredient that Polaris introduced, is derived from the vitamin-, protein-, pigment-, and enzyme-rich microalgae (Schizochytrium sp.). The component provided a sustainable and plant-based source for polyunsaturated fatty acids (PUFAs).

Segmentation

Global EPA And DHA Market: Segmentation

By Type

• Eicosapentaenoic Acid (EPA)
• Docosahexaenoic Acid (DHA)

By Source

• Fish Oil
• Algae Oil
• Krill Oil
• Other Sources

By Applications

• Infant Formulae
• Dietary Supplements
• Fortified Food and Beverages
• Pharmaceuticals
• Other Applications

By Regions

• North America
• Europe
• Asia-Pacific
• LAMEA